Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies.

Passweg JR, Baldomero H, Basak GW, Chabannon C, Corbacioglu S, Duarte R, Kuball J, Lankester A, Montoto S, de Latour RP, Snowden JA, Styczynski J, Yakoub-Agha I, Arat M, Mohty M, Kröger N; European Society for Blood and Marrow Transplantation (EBMT).

Bone Marrow Transplant. 2019 Feb 6. doi: 10.1038/s41409-019-0465-9. [Epub ahead of print]

PMID:
30728439
2.

Early-onset severe infections in allogeneic hematopoietic stem cell transplantation recipients with graft failure.

Alcazer V, Conrad A, Valour F, Bachy E, Salles G, Huynh A, de Latour RP, Labussière-Wallet H, Ader F; Lyon HEMINF study group.

Am J Hematol. 2019 Jan 20. doi: 10.1002/ajh.25406. [Epub ahead of print] No abstract available.

PMID:
30663089
3.

Autologous haematopoietic stem cell transplantation (AHSCT) in autoimmune disease adult patients in France: analysis of the long-term outcome from the French Society for Bone Marrow Transplantation and Cellular Therapy (SFGM-TC).

Guillaume-Jugnot P, Badoglio M, Labopin M, Terriou L, Yakoub-Agha I, Martin T, Lioure B, Marjanovic Z, Blaise D, Nguyen S, Pugnet G, Huynh A, Deligny C, Seinturier C, Garban F, Swiader L, Bay JO, Braun T, de Latour RP, Rubio MT, Farge D.

Clin Rheumatol. 2019 Jan 21. doi: 10.1007/s10067-019-04435-2. [Epub ahead of print]

PMID:
30663016
4.

Clofarabine/busulfan-based reduced intensity conditioning regimens provides very good survivals in acute myeloid leukemia patients in complete remission at transplant: a retrospective study on behalf of the SFGM-TC.

Bourgeois AL, Labopin M, Leclerc M, de Latour RP, Bourhis JH, Ceballos P, Orvain C, Wallet HL, Bilger K, Blaise D, Rubio MT, Guillaume T, Mohty M, Chevallier P; Société Francophone de Greffe de Moelle et de Thérapie Cellulaire.

Oncotarget. 2018 Nov 27;9(93):36603-36612. doi: 10.18632/oncotarget.26391. eCollection 2018 Nov 27.

5.

Impact of T-cell depletion strategies on outcomes following hematopoietic stem cell transplantation for idiopathic aplastic anemia: A study on behalf of the European blood and marrow transplant severe aplastic anemia working party.

Samarasinghe S, Clesham K, Iacobelli S, Sbianchi G, Knol C, Hamladji RM, Socié G, Aljurf M, Koh M, Sengeloev H, Dalle JH, Robinson S, Van Lint MT, Halkes CJM, Beelen D, Mufti GJ, Snowden J, Blaise D, de Latour RP, Marsh J, Dufour C, Risitano AM; Severe Aplastic Anaemia Working Party of the EBMT.

Am J Hematol. 2019 Jan;94(1):80-86. doi: 10.1002/ajh.25314. Epub 2018 Nov 25.

PMID:
30328134
6.

Aplastic anemia in the elderly: a nationwide survey on behalf of the French Reference Center for Aplastic Anemia.

Contejean A, Resche-Rigon M, Tamburini J, Alcantara M, Jardin F, Lengliné E, Adès L, Bouscary D, Marçais A, Lebon D, Chabrot C, Terriou L, Barraco F, Banos A, Bussot L, Cahn JY, Hirsch P, Maillard N, Simon L, Fornecker LM, Socié G, de Latour RP, de Fontbrune FS.

Haematologica. 2019 Feb;104(2):256-262. doi: 10.3324/haematol.2018.198440. Epub 2018 Sep 27.

7.

Scoring System Based on Post-Transplant Complications in Patients after Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome: A Study from the SFGM-TC.

Caulier A, Drumez E, Gauthier J, Robin M, Blaise D, Beguin Y, Michallet M, Chevallier P, Bay JO, Vigouroux S, Desbrosses Y, Cornillon J, Nguyen S, Dauriac C, de Latour RP, Lioure B, Rohrlich PS, Carré M, Bourhis JH, Huynh A, Suarez F, Garnier F, Duhamel A, Yakoub-Agha I.

Curr Res Transl Med. 2019 Feb;67(1):8-15. doi: 10.1016/j.retram.2018.08.003. Epub 2018 Sep 8.

8.

Late effects after hematopoietic stem cell transplantation for β-thalassemia major: the French national experience.

Rahal I, Galambrun C, Bertrand Y, Garnier N, Paillard C, Frange P, Pondarré C, Dalle JH, de Latour RP, Michallet M, Steschenko D, Moshous D, Lutz P, Stephan JL, Rohrlich PS, Yakoub-Agha I, Bernaudin F, Piguet C, Aladjidi N, Badens C, Berger C, Socié G, Dumesnil C, Castex MP, Poirée M, Lambilliotte A, Thomas C, Simon P, Auquier P, Michel G, Loundou A, Agouti I, Thuret I.

Haematologica. 2018 Jul;103(7):1143-1149. doi: 10.3324/haematol.2017.183467. Epub 2018 Mar 29.

9.

Extending autologous transplantation as first line therapy in multiple myeloma patients with severe renal impairment: a retrospective study by the SFGM-TC.

Augeul-Meunier K, Chretien ML, Stoppa AM, Karlin L, Benboubker L, Diaz JMT, Mohty M, Yakoub-Agha I, Bay JO, Perrot A, Bulabois CE, Huynh A, Mercier M, Frenzel L, Avet-Loiseau H, de Latour RP, Cornillon J.

Bone Marrow Transplant. 2018 Jun;53(6):749-755. doi: 10.1038/s41409-018-0122-8. Epub 2018 Mar 9.

PMID:
29523884
10.

Hematopoietic stem cell transplantation for patients with paroxysmal nocturnal hemoglobinuria previously treated with eculizumab: a retrospective study of 21 patients from SFGM-TC centers.

Vallet N, de Fontbrune FS, Loschi M, Desmier D, Villate A, Barraco F, Chevallier P, Terriou L, Yakoub-Agha I, Ruggeri A, Mohty M, Maillard N, Rohrlich PS, Ceballos P, Nguyen S, Poiré X, Guillerm G, Tabrizi R, Farhi J, Devillier R, Rubio MT, Socié G, de Latour RP; Société Francophone de Greffe de Moelle et Thérapie Cellulaire.

Haematologica. 2018 Mar;103(3):e103-e105. doi: 10.3324/haematol.2017.182360. Epub 2017 Dec 21. No abstract available.

11.

Nationwide survey on the use of eltrombopag in patients with severe aplastic anemia: a report on behalf of the French Reference Center for Aplastic Anemia.

Lengline E, Drenou B, Peterlin P, Tournilhac O, Abraham J, Berceanu A, Dupriez B, Guillerm G, Raffoux E, de Fontbrune FS, Ades L, Balsat M, Chaoui D, Coppo P, Corm S, Leblanc T, Maillard N, Terriou L, Socié G, de Latour RP.

Haematologica. 2018 Feb;103(2):212-220. doi: 10.3324/haematol.2017.176339. Epub 2017 Nov 23.

12.

Combined intensive immunosuppression and eculizumab for aplastic anemia in the context of hemolytic paroxysmal nocturnal hemoglobinuria: a retrospective analysis.

Pagliuca S, Risitano AM, De Fontbrune FS, Robin M, Iori AP, Marotta S, Michonneau D, Villate A, Desmier D, Socié G, De Latour RP.

Bone Marrow Transplant. 2018 Jan;53(1):105-107. doi: 10.1038/bmt.2017.220. Epub 2017 Nov 13. No abstract available.

PMID:
29131151
13.

Design of the DREPAGREFFE trial: A prospective controlled multicenter study evaluating the benefit of genoidentical hematopoietic stem cell transplantation over chronic transfusion in sickle cell anemia children detected to be at risk of stroke by transcranial Doppler (NCT 01340404).

Chevret S, Verlhac S, Ducros-Miralles E, Dalle JH, de Latour RP, de Montalembert M, Benkerrou M, Pondarré C, Thuret I, Guitton C, Lesprit E, Etienne-Julan M, Elana G, Vannier JP, Lutz P, Neven B, Galambrun C, Paillard C, Runel C, Jubert C, Arnaud C, Kamdem A, Brousse V, Missud F, Petras M, Doumdo-Divialle L, Berger C, Fréard F, Taieb O, Drain E, Elmaleh M, Vasile M, Khelif Y, Bernaudin M, Chadebech P, Pirenne F, Socié G, Bernaudin F.

Contemp Clin Trials. 2017 Nov;62:91-104. doi: 10.1016/j.cct.2017.08.008. Epub 2017 Aug 15.

PMID:
28821470
14.

Biallelic inactivation of REV7 is associated with Fanconi anemia.

Bluteau D, Masliah-Planchon J, Clairmont C, Rousseau A, Ceccaldi R, d'Enghien CD, Bluteau O, Cuccuini W, Gachet S, de Latour RP, Leblanc T, Socié G, Baruchel A, Stoppa-Lyonnet D, D'Andrea AD, Soulier J.

J Clin Invest. 2017 Mar 1;127(3):1117. doi: 10.1172/JCI92946. Epub 2017 Mar 1. No abstract available.

15.

Immunothérapie et greffe de cellules souches hématopoïétiques allogéniques.

de Fontbrune FS, Cavalieri D, Leclerc M, Beckerich F, Maury S, de Latour RP, N-Guyen S, Bay JO.

Bull Cancer. 2016 Nov;103 Suppl 1:S164-S174. doi: 10.1016/S0007-4551(16)30375-7. French. Erratum in: Bull Cancer. 2017 May;104(5):494.

PMID:
28057181
16.

Graft-Versus-Host Disease in Adolescents and Young Adults (15-24 Years Old) After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Leukemia in First Complete Remission.

Vignon M, Andreoli A, Dhédin N, Lengliné E, Masson E, Robin M, Granier C, Larghero J, Schlageter MH, de Latour RP, Socié G, Boissel N.

J Adolesc Young Adult Oncol. 2017 Jun;6(2):299-306. doi: 10.1089/jayao.2016.0060. Epub 2016 Dec 16.

PMID:
27983886
17.

Fecal calprotectin and α1-antitrypsin dynamics in gastrointestinal GvHD.

O'Meara A, Kapel N, Xhaard A, Sicre de Fontbrune F, Manéné D, Dhedin N, de Latour RP, Socié G, Robin M.

Bone Marrow Transplant. 2015 Aug;50(8):1105-9. doi: 10.1038/bmt.2015.109. Epub 2015 May 11.

PMID:
25961766
18.

HLA-matched allogeneic stem cell transplantation improves outcome of higher risk myelodysplastic syndrome A prospective study on behalf of SFGM-TC and GFM.

Robin M, Porcher R, Adès L, Raffoux E, Michallet M, François S, Cahn JY, Delmer A, Wattel E, Vigouroux S, Bay JO, Cornillon J, Huynh A, Nguyen S, Rubio MT, Vincent L, Maillard N, Charbonnier A, de Latour RP, Reman O, Dombret H, Fenaux P, Socié G.

Leukemia. 2015 Jul;29(7):1496-501. doi: 10.1038/leu.2015.37. Epub 2015 Feb 13.

PMID:
25676424
19.

Use of Eculizumab in Patients With Allogeneic Stem Cell Transplant-Associated Thrombotic Microangiopathy: A Study From the SFGM-TC.

de Fontbrune FS, Galambrun C, Sirvent A, Huynh A, Faguer S, Nguyen S, Bay JO, Neven B, Moussi J, Simon L, Xhaard A, Resche-Riggon M, O'Meara A, Fremeaux-Bacchi V, Veyradier A, Socié G, Coppo P, de Latour RP.

Transplantation. 2015 Sep;99(9):1953-9. doi: 10.1097/TP.0000000000000601.

PMID:
25651309
20.

Equivalent outcomes using reduced intensity or conventional myeloablative conditioning transplantation for patients aged 35 years and over with AML.

Sébert M, Porcher R, Robin M, Adès L, Boissel N, Raffoux E, Xhaard A, Dhedin N, Larghero J, Himberlin C, Delmer A, Fenaux P, Dombret H, Socié G, de Latour RP.

Bone Marrow Transplant. 2015 Jan;50(1):74-81. doi: 10.1038/bmt.2014.199. Epub 2014 Sep 22.

PMID:
25243624
21.

Estimating the treatment effect from non-randomized studies: The example of reduced intensity conditioning allogeneic stem cell transplantation in hematological diseases.

Resche-Rigon M, Pirracchio R, Robin M, De Latour RP, Sibon D, Ades L, Ribaud P, Fermand JP, Thieblemont C, Socié G, Chevret S.

BMC Blood Disord. 2012 Aug 16;12:10. doi: 10.1186/1471-2326-12-10.

22.

Extensive chronic GVHD is associated with donor blood CD34+ cell count after G-CSF mobilization in non-myeloablative allogeneic PBSC transplantation.

Dhédin N, Prébet T, De Latour RP, Katsahian S, Kuentz M, Piard N, Réa D, Norol F, Jouet JP, Ribeil JA, Tabrizi R, Rio B, Lioure B, Tiberghien P, Bourhis JH, Sirvent A, Bordigoni P, Blaise D, Michallet M, Vernant JP.

Bone Marrow Transplant. 2012 Dec;47(12):1564-8. doi: 10.1038/bmt.2012.75. Epub 2012 May 21.

PMID:
22609881
23.

Possible pathogenic role of the transmembrane isoform of CD160 NK lymphocyte receptor in paroxysmal nocturnal hemoglobinuria.

Giustiniani J, Alaoui SS, Marie-Cardine A, Bernard J, Olive D, Bos C, Razafindratsita A, Petropoulou A, de Latour RP, Le Bouteiller P, Bagot M, Socié G, Bensussan A.

Curr Mol Med. 2012 Feb;12(2):188-98.

PMID:
22172098
24.

Steroid-refractory acute GVHD: lack of long-term improved survival using new generation anticytokine treatment.

Xhaard A, Rocha V, Bueno B, de Latour RP, Lenglet J, Petropoulou A, Rodriguez-Otero P, Ribaud P, Porcher R, Socié G, Robin M.

Biol Blood Marrow Transplant. 2012 Mar;18(3):406-13. doi: 10.1016/j.bbmt.2011.06.012. Epub 2011 Jul 4.

25.

Association of HLA-G low expressor genotype with severe acute graft-versus-host disease after sibling bone marrow transplantation.

Boukouaci W, Busson M, Fortier C, Amokrane K, de Latour RP, Robin M, Krishnamoorthy R, Toubert A, Charron D, Socié G, Tamouza R.

Front Immunol. 2011 Dec 27;2:74. doi: 10.3389/fimmu.2011.00074. eCollection 2011.

26.

Aplastic anemia & MDS International Foundation (AA&MDSIF): Bone Marrow Failure Disease Scientific Symposium 2010.

Malcovati L, de Latour RP, Risitano A.

Leuk Res. 2011 Mar;35(3):291-4. doi: 10.1016/j.leukres.2010.10.010. Epub 2010 Oct 30.

PMID:
21036397
27.

The graft-versus-leukemia effect is mainly restricted to NIH-defined chronic graft-versus-host disease after reduced intensity conditioning before allogeneic stem cell transplantation.

Thepot S, Zhou J, Perrot A, Robin M, Xhaard A, de Latour RP, Ades L, Ribaud P, Petropoulou AD, Porcher R, Socié G.

Leukemia. 2010 Nov;24(11):1852-8. doi: 10.1038/leu.2010.187. Epub 2010 Sep 9.

PMID:
20827288
28.

Th17 immune responses contribute to the pathophysiology of aplastic anemia.

de Latour RP, Visconte V, Takaku T, Wu C, Erie AJ, Sarcon AK, Desierto MJ, Scheinberg P, Keyvanfar K, Nunez O, Chen J, Young NS.

Blood. 2010 Nov 18;116(20):4175-84. doi: 10.1182/blood-2010-01-266098. Epub 2010 Aug 23.

29.

Splenectomy after allogeneic haematopoietic stem cell transplantation in patients with primary myelofibrosis.

Robin M, Espérou H, de Latour RP, Petropoulou AD, Xhaard A, Ribaud P, Socié G.

Br J Haematol. 2010 Sep;150(6):721-4. doi: 10.1111/j.1365-2141.2010.08276.x. No abstract available.

PMID:
20618333
30.

Tandem autologous non-myeloablative allogeneic transplantation in patients with multiple myeloma relapsing after a first high dose therapy.

Karlin L, Arnulf B, Chevret S, Ades L, Robin M, De Latour RP, Malphettes M, Kabbara N, Asli B, Rocha V, Fermand JP, Socie G.

Bone Marrow Transplant. 2011 Feb;46(2):250-6. doi: 10.1038/bmt.2010.90. Epub 2010 Apr 19.

PMID:
20400980
31.

Long-term immune deficiency after allogeneic stem cell transplantation: B-cell deficiency is associated with late infections.

Corre E, Carmagnat M, Busson M, de Latour RP, Robin M, Ribaud P, Toubert A, Rabian C, Socié G.

Haematologica. 2010 Jun;95(6):1025-9. doi: 10.3324/haematol.2009.018853. Epub 2010 Feb 4.

32.

Evaluation of hemostasis and endothelial function in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab.

Helley D, de Latour RP, Porcher R, Rodrigues CA, Galy-Fauroux I, Matheron J, Duval A, Schved JF, Fischer AM, Socié G; French Society of Hematology.

Haematologica. 2010 Apr;95(4):574-81. doi: 10.3324/haematol.2009.016121. Epub 2010 Jan 15.

33.

Initial liver involvement in acute GVHD is predictive for nonrelapse mortality.

Robin M, Porcher R, de Castro R, Fisher G, de Latour RP, Ribaud P, Petropoulou AD, Rocha V, Devergie A, Mary JY, Socié G.

Transplantation. 2009 Nov 15;88(9):1131-6. doi: 10.1097/TP.0b013e3181bc2583.

PMID:
19898210
34.

Chronic kidney dysfunction in patients alive without relapse 2 years after allogeneic hematopoietic stem cell transplantation.

Abboud I, Porcher R, Robin M, de Latour RP, Glotz D, Socié G, Peraldi MN.

Biol Blood Marrow Transplant. 2009 Oct;15(10):1251-7. doi: 10.1016/j.bbmt.2009.05.016.

35.

Coeliac disease and aplastic anaemia: a specific entity?

Salmeron G, Patey N, de Latour RP, Raffoux E, Gluckman E, Brousse N, Socié G, Robin M.

Br J Haematol. 2009 Jun;146(1):122-4. doi: 10.1111/j.1365-2141.2009.07719.x. Epub 2009 May 5. No abstract available.

PMID:
19438483
36.

Hepatitis C virus and allogeneic stem cell transplantation still matters!

Socié G, de Latour RP, McDonald GB.

Haematologica. 2009 Feb;94(2):170-2. doi: 10.3324/haematol.2008.002048. Review. No abstract available.

37.

Polyomaviruses KI and WU in immunocompromised patients with respiratory disease.

Mourez T, Bergeron A, Ribaud P, Scieux C, de Latour RP, Tazi A, Socié G, Simon F, LeGoff J.

Emerg Infect Dis. 2009 Jan;15(1):107-9. doi: 10.3201/eid1501.080758.

38.

Double cord blood transplantation in patients with high risk bone marrow failure syndromes.

Ruggeri A, de Latour RP, Rocha V, Larghero J, Robin M, Rodrigues CA, Traineau R, Ribaud P, Ferry C, Devergie A, Gluckman E, Socié G.

Br J Haematol. 2008 Nov;143(3):404-8. doi: 10.1111/j.1365-2141.2008.07364.x. Epub 2008 Aug 10.

PMID:
18699847
39.

Impact of comorbidity indexes on non-relapse mortality.

Xhaard A, Porcher R, Chien JW, de Latour RP, Robin M, Ribaud P, Rocha V, Devergie A, Ferry C, Martin PJ, Socié G.

Leukemia. 2008 Nov;22(11):2062-9. doi: 10.1038/leu.2008.197. Epub 2008 Aug 7.

40.

Patterns of cytomegalovirus reactivation are associated with distinct evolutive profiles of immune reconstitution after allogeneic hematopoietic stem cell transplantation.

Moins-Teisserenc H, Busson M, Scieux C, Bajzik V, Cayuela JM, Clave E, de Latour RP, Agbalika F, Ribaud P, Robin M, Rocha V, Gluckman E, Charron D, Socié G, Toubert A.

J Infect Dis. 2008 Sep 15;198(6):818-26. doi: 10.1086/591185.

PMID:
18666855
41.

Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories.

de Latour RP, Mary JY, Salanoubat C, Terriou L, Etienne G, Mohty M, Roth S, de Guibert S, Maury S, Cahn JY, Socié G; French Society of Hematology; French Association of Young Hematologists.

Blood. 2008 Oct 15;112(8):3099-106. doi: 10.1182/blood-2008-01-133918. Epub 2008 Jun 5.

42.

Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Société Francaise de Greffe de Moëlle et de Thérapie Cellulaire.

Le Gouill S, Milpied N, Buzyn A, De Latour RP, Vernant JP, Mohty M, Moles MP, Bouabdallah K, Bulabois CE, Dupuis J, Rio B, Gratecos N, Yakoub-Agha I, Attal M, Tournilhac O, Decaudin D, Bourhis JH, Blaise D, Volteau C, Michallet M; Société Française de Greffe de Moëlle et de Thérapie Cellulaire.

J Clin Oncol. 2008 May 10;26(14):2264-71. doi: 10.1200/JCO.2007.14.1366. Epub 2008 Apr 7.

PMID:
18390969
43.

Influence of bone marrow nucleated red blood cell dose on outcome after allogeneic haematopoietic stem cell transplantation.

Robin M, Kernèis S, Porcher R, de Latour RP, Traineau R, Ribaud P, Rocha V, Devergie A, Marolleau JP, Benburan M, Socié G, Larghero J.

Br J Haematol. 2008 Mar;140(6):725-7. doi: 10.1111/j.1365-2141.2008.07009.x. No abstract available.

PMID:
18302719
44.

Donor CTLA-4 +49 A/G*GG genotype is associated with chronic GVHD after HLA-identical haematopoietic stem-cell transplantations.

Azarian M, Busson M, Lepage V, Charron D, Toubert A, Loiseau P, de Latour RP, Rocha V, Socié G.

Blood. 2007 Dec 15;110(13):4623-4. No abstract available.

45.

Breakthrough invasive aspergillosis in allogeneic haematopoietic stem cell transplant recipients treated with caspofungin.

Madureira A, Bergeron A, Lacroix C, Robin M, Rocha V, de Latour RP, Ferry C, Devergie A, Lapalu J, Gluckmana E, Socié G, Ghannoum M, Ribaud P.

Int J Antimicrob Agents. 2007 Dec;30(6):551-4.

PMID:
18029149
46.

Risk factors for late infections after allogeneic hematopoietic stem cell transplantation from a matched related donor.

Robin M, Porcher R, De Castro Araujo R, de Latour RP, Devergie A, Rocha V, Larghero J, Adès L, Ribaud P, Mary JY, Socié G.

Biol Blood Marrow Transplant. 2007 Nov;13(11):1304-12. Epub 2007 Sep 7.

47.

Palivizumab treatment of respiratory syncytial virus infection after allogeneic hematopoietic stem cell transplantation.

de Fontbrune FS, Robin M, Porcher R, Scieux C, de Latour RP, Ferry C, Rocha V, Boudjedir K, Devergie A, Bergeron A, Gluckman E, Azoulay E, Lapalu J, Socié G, Ribaud P.

Clin Infect Dis. 2007 Oct 15;45(8):1019-24. Epub 2007 Sep 11.

PMID:
17879919
48.

Microbial contamination of BM products before and after processing: a report of incidence and immediate adverse events in 257 grafts.

Vanneaux V, Foïs E, Robin M, Rea D, de Latour RP, Biscay N, Chantre E, Robert I, Wargnier A, Traineau R, Benbunan M, Marolleau J, Socié G, Larghero J.

Cytotherapy. 2007;9(5):508-13.

PMID:
17786612
49.

Long-term outcomes after allogeneic stem cell transplantation for children with hematological malignancies.

Ferry C, Gemayel G, Rocha V, Labopin M, Esperou H, Robin M, de Latour RP, Ribaud P, Devergie A, Leblanc T, Gluckman E, Baruchel A, Socié G.

Bone Marrow Transplant. 2007 Aug;40(3):219-24. Epub 2007 May 28.

PMID:
17530002
50.

Mobilization of peripheral blood progenitor cells after DHAP regimen with or without rituximab: a large multicenter comparative study in patients with malignant lymphoma.

de Latour RP, Chaoui D, Bourhis JH, Belhocine R, Park S, Legrand O, Brault P, Rio B, Heshmati F, Assouad S, Decaudin D.

Leuk Lymphoma. 2007 May;48(5):897-904.

PMID:
17487733

Supplemental Content

Loading ...
Support Center